GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England. ... Pharmacist cautions against self-medicating with ozempic for dementia risk reduction.

Ozempic was also linked to a greater reduction in Alzheimer’s risk compared with metformin and several other older diabetes drugs. Brain health benefits of Ozempic didn’t change based on ...

Blockbuster weight loss jabs relied on by millions of slimmers could slash the risk of developing dementia, two major studies have suggested. Semaglutide — the powerful ingredient behind Wegovy ...

READ MORE: Ozempic and Wegovy may reduce dementia risk, study suggests ; ... Mice treated with the drug showed a 62 percent reduction in tau tangles compared to the untreated mice.

Notably, previous research has determined that diabetes patients are at a greater risk of developing dementia. Patients who took Ozempic also saw an 18% reduction in nicotine dependence compared ...

Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,” the study author said.

A study finds a drug known for weight loss may also help to reduce dementia. The study looked at semaglutide, the scientific name for Novo Nordisk's (NVO) (DK:NOVO.B) Ozempic, with the intent of ...

The study used data on US veterans with type 2 diabetes, some of whom were given Ozempic or Wegovy and some more standard drugs - to measure their effect on 175 other illnesses.

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on the body, researchers say. The analysis, involving about two million ...